- Market opportunity may expand to $2.3 billion for Type 1 Gaucher Disease patients
- Expanding market opportunity to treat Type 1 patients based on oral dosage in an existing large and profitable market
Type 1 Gaucher Disease Market Opportunity
- Current $1.5 billion U.S. market for intravenous administered ERT therapy;
- Only 50-60% of Type 1 patients are treated
- ERAD plans to introduce an oral formulation of our drug
- We believe newly diagnosed Type 1 patients will be preferentially started on our therapy and existing Type 1 patients may switch
- $2.35 billion U.S. market opportunity in Type 1
- 8,000 total addressable U.S. patient population (100%)
- Potentially applicable in treating the Parkinson-like symptoms associated with both Gaucher Disease patients and disease carriers